Mechanism of action of bisphosphonates - PubMed (original) (raw)
Review
Mechanism of action of bisphosphonates
Alfred A Reszka et al. Curr Osteoporos Rep. 2003 Sep.
Abstract
In recent years, substantial progress has been made in understanding the mechanism for bisphosphonate suppression of bone turnover. Bisphosphonates can now be distinguished based on their molecular and cellular mechanisms of action. Simple bisphosphonates such as clodronate and etidronate inhibit bone resorption through induction of osteoclast apoptosis. Clodronate, and perhaps etidronate, triggers apoptosis by generating a toxic analog of adenosine triphosphate, which then targets the mitochondria, the energy center within the cell. For nitrogen-containing bisphosphonates, the direct intracellular target is the enzyme farnesyl diphosphate synthase in the cholesterol biosynthetic pathway. Its inhibition suppresses a process called protein geranylgeranylation, which is essential for the basic cellular processes required for osteoclastic bone resorption. Although nitrogen-containing bisphosphonates can induce osteoclast apoptosis, this is not necessary for their inhibition of bone resorption.
Similar articles
- [Basic Studies on the Mechanism, Prevention, and Treatment of Osteonecrosis of the Jaw Induced by Bisphosphonates].
Endo Y, Funayama H, Yamaguchi K, Monma Y, Yu Z, Deng X, Oizumi T, Shikama Y, Tanaka Y, Okada S, Kim S, Kiyama T, Bando K, Shima K, Suzuki H, Takahashi T. Endo Y, et al. Yakugaku Zasshi. 2020;140(1):63-79. doi: 10.1248/yakushi.19-00125. Yakugaku Zasshi. 2020. PMID: 31902887 Review. Japanese. - Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Luckman SP, et al. J Bone Miner Res. 1998 Apr;13(4):581-9. doi: 10.1359/jbmr.1998.13.4.581. J Bone Miner Res. 1998. PMID: 9556058 - Bisphosphonates: preclinical aspects and use in osteoporosis.
Fleisch HA. Fleisch HA. Ann Med. 1997 Feb;29(1):55-62. doi: 10.3109/07853899708998743. Ann Med. 1997. PMID: 9073324 Review. - Bisphosphonate therapy.
Licata AA. Licata AA. Am J Med Sci. 1997 Jan;313(1):17-22. doi: 10.1097/00000441-199701000-00004. Am J Med Sci. 1997. PMID: 9001162 Review.
Cited by
- Dual Modification of Porous Ca-P/PLA Composites with APTES and Alendronate Improves Their Mechanical Strength and Cytobiocompatibility towards Human Osteoblasts.
Biernat M, Szwed-Georgiou A, Rudnicka K, Płociński P, Pagacz J, Tymowicz-Grzyb P, Woźniak A, Włodarczyk M, Urbaniak MM, Krupa A, Rusek-Wala P, Karska N, Rodziewicz-Motowidło S. Biernat M, et al. Int J Mol Sci. 2022 Nov 18;23(22):14315. doi: 10.3390/ijms232214315. Int J Mol Sci. 2022. PMID: 36430791 Free PMC article. - Potentiation of the cytotoxic activity of copper by polyphosphate on biofilm-producing bacteria: a bioinspired approach.
Müller WE, Wang X, Guo YW, Schröder HC. Müller WE, et al. Mar Drugs. 2012 Oct 25;10(11):2369-87. doi: 10.3390/md10112369. Mar Drugs. 2012. PMID: 23203265 Free PMC article. - 2-alkylaminoethyl-1,1-bisphosphonic acids are potent inhibitors of the enzymatic activity of Trypanosoma cruzi squalene synthase.
Rodrígues-Poveda CA, González-Pacanowska D, Szajnman SH, Rodríguez JB. Rodrígues-Poveda CA, et al. Antimicrob Agents Chemother. 2012 Aug;56(8):4483-6. doi: 10.1128/AAC.00796-12. Epub 2012 May 14. Antimicrob Agents Chemother. 2012. PMID: 22585217 Free PMC article. - Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents.
Recher M, Barboza AP, Li ZH, Galizzi M, Ferrer-Casal M, Szajnman SH, Docampo R, Moreno SN, Rodriguez JB. Recher M, et al. Eur J Med Chem. 2013 Feb;60:431-40. doi: 10.1016/j.ejmech.2012.12.015. Epub 2012 Dec 20. Eur J Med Chem. 2013. PMID: 23318904 Free PMC article. - Design, Synthesis, Pharmacokinetics, and Biodistribution of a Series of Bone-Targeting EP4 Receptor Agonist Prodrugs for Treatment of Osteoporosis and Other Bone Conditions.
Thévenin M, Chen G, Kantham S, Sun C, Glogauer M, Young RN. Thévenin M, et al. ACS Pharmacol Transl Sci. 2021 Mar 10;4(2):908-925. doi: 10.1021/acsptsci.1c00027. eCollection 2021 Apr 9. ACS Pharmacol Transl Sci. 2021. PMID: 33860210 Free PMC article.
References
- J Cell Sci. 1995 Jun;108 ( Pt 6):2285-92 - PubMed
- Curr Rheumatol Rep. 2003 Feb;5(1):65-74 - PubMed
- J Bone Miner Res. 2000 Aug;15(8):1467-76 - PubMed
- J Bone Miner Res. 1998 Nov;13(11):1668-78 - PubMed
- J Bone Miner Res. 1994 Dec;9(12):1875-82 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources